SWOG clinical trial number
S0635
A Phase II Trial of the Combination of OSI-774 (Erlotinib; NSC-718781) and Bevacizumab (Rhumab VEGF; NSC-704865) in Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma with BAC Features
95% Accrual
Accrual
95%
Closed
Phase
95% Accrual
Accrual
95%
Abbreviated Title
Phase II OSI-774/Bevacizumab in St. IIIB and IV BAC and AdenoBAC
Activated
07/15/2007
Closed
08/15/2011
Participants
Research committees
Lung Cancer
Treatment
Bevacizumab
Erlotinib
Eligibility Criteria Expand/Collapse
Publication Information Expand/Collapse
Other Clinical Trials
S2414
SWOG Clinical Trial Number
Research Committee(s)
Lung Cancer
Symptom Control and Quality of Life
Activated
03/14/2025
1% Accrual
Accrual
1%
Open
Phase
A082002
SWOG Clinical Trial Number
Research Committee(s)
Lung Cancer
Activated
12/21/2021
Open
Phase
CTSU/NRG-LU007
SWOG Clinical Trial Number
Research Committee(s)
Lung Cancer
Activated
08/17/2020
Open